Evidence map›Paper›PMID 34830889›Full record

ArticleCancers2021

Can Naloxegol Therapy Improve Quality of Life in Patients with Advanced Cancer?

Rita Ostan, Giuseppe Gambino, Italo Malavasi, Gianluca Ronga, Maria Solipaca, Michela Spunghi, Silvia Varani, Raffaella Pannuti, Enrico Ruggeri

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04294550 (A Multicenter, Observational Prospective Study on Quality of Life), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04294550 completednot on this map

A Multicenter, Observational Prospective Study on Quality of Life (QOL) in Advanced Cancer Patients With Opioid-induced Constipation (OIC) Treated at Home With Naloxegol According to the Clinical Practice

TypeobservationalSponsorFondazione ANT Franco Pannuti ETSRan2018 to 2021Enrolled250ConditionsOpioid Use, Constipation Drug Induced, CancerArmsNaloxegol
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Rita OstanNational Tumor Assistance (ANT), Via Jacopo di Paolo, 36-40128 Bologna, Italy.ORCID 0000-0002-0299-2811
Giuseppe GambinoNational Tumor Assistance (ANT), Via Jacopo di Paolo, 36-40128 Bologna, Italy.ORCID 0000-0002-2992-1853
Italo MalavasiNational Tumor Assistance (ANT), Via Jacopo di Paolo, 36-40128 Bologna, Italy.
Gianluca RongaNational Tumor Assistance (ANT), Via Jacopo di Paolo, 36-40128 Bologna, Italy.
Maria SolipacaNational Tumor Assistance (ANT), Via Jacopo di Paolo, 36-40128 Bologna, Italy.
Michela SpunghiNational Tumor Assistance (ANT), Via Jacopo di Paolo, 36-40128 Bologna, Italy.
Silvia VaraniNational Tumor Assistance (ANT), Via Jacopo di Paolo, 36-40128 Bologna, Italy.
Raffaella PannutiNational Tumor Assistance (ANT), Via Jacopo di Paolo, 36-40128 Bologna, Italy.
Enrico RuggeriNational Tumor Assistance (ANT), Via Jacopo di Paolo, 36-40128 Bologna, Italy.ORCID 0000-0002-1622-5621
ANT Foundation Italy Onlus · IT

Funding

Kyowa Kirin International (United Kingdom) non conditioning funding
6 · The paper itself

Abstract

This observational study aims to evaluate the efficacy of naloxegol therapy in resolving opioid-induced constipation (OIC) and in improving the quality of life in a home palliative care cancer setting. Advanced cancer patients with OIC (Rome IV criteria) not relieved by laxatives started a naloxegol therapy 25 mg/day for 4 weeks. Quality of life was evaluated by Patient Assessment of Constipation Quality-of-Life (PAC-QoL) at day 0 and day 28; background pain by Numerical Rating Scale, number of weekly spontaneous bowel movements and Bowel Function Index (BFI) were evaluated at day 0 and every week. Seventy-eight patients who completed the 4-week study improved all four PAC-QoL dimensions (physical and psychological discomfort, worries/concerns and satisfaction level). Weekly spontaneous bowel movements increased and BFI improved. Background pain reduced after seven days and remained lower during the following weeks. Seventy-two patients dropped out the study before day 28 with a reduced survival compared to patients completing the study. Even in these patients, an improvement of bowel function was observed after two weeks. Naloxegol was effective in improving the quality of life, resolving OIC and reducing overall pain in patients with advanced cancer.

Indexed as

antagonistscancernaloxegolopioid-induced constipationopioid receptorpalliative carequality of life

Identifiers

PMID34830889
PMCPMC8616145
OpenAlexW3213492161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.